PHVS.US Pharvaris BV

Healthcare Biotechnology USA Stocks
33.36 USD
Close of Nov 15, 2026
23.15 43.25
Market cap
USD 2.36B
P/E
-
P/B
8.04x
ROE
-68.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PHVS.US undervalued?

Graham number

The Graham number of Pharvaris BV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharvaris BV fundamental analysis

No fundamental analysis for Pharvaris BV yet.

Pharvaris BV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharvaris BV

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase…

Full company profile